Biotechnology company focused on standardized, quality-controlled extraction of psychoactive compounds from plants and fungi HAVN Life Sciences Inc. (CSE: HAVN) (OTCMKTS: HAVLF) announced having secured a purchase order for natural extracted psilocybin from Revive Therapeutics Ltd. (CSE: RVV) (OTCMKTS: RVVTF) for use in clinical research studies.
According to the supply agreement, HAVN Life will export naturally extracted GMP psilocybin from its Jamaica based facility into the United States through its distribution partner Mycrodose Therapeutics Inc. to be used by the University of Wisconsin-Madison (UW-Madison) which is a Contact Research Organization (CRO) for Revive Therapeutics.
The shipped naturally derived psilocybin will enable UW-Madison to carry out research and formulation work to finalize dosing and delivery mechanisms in support of various studies which will be sponsored by Revive Therapeutics using an oral-thin and hydra-gel delivery systems of psychedelics to cure mental health disorders.
“We are so pleased to be able to supply our naturally derived, GMP psilocybin for this potentially ground-breaking research related to addiction disorders. It is our hope that research like this will help in the push toward the rescheduling of Schedule I compounds like psilocybin and psilocin, making treatment more accessible and helping to ease the growing mental health and addiction crisis we are facing today,” said the CEO of HAVN Life, Tim Moore.
On the other side the CEO of Revive Therapeutics, Michael Frank, expressed how as a company they are delighted to work with HAVN Life and even looking forward for future partnerships.
“We are excited to work with HAVN Life to move forward with our investigational clinical trials including our project in Antigua. We are eager to advance the science on botanically-derived ingredients such as psilocin and psilocybin,” said the CEO.
